VAC-3S: Interim Phase I/IIa data

Interim data from a double-blind, placebo-controlled, French Phase I/IIa trial in 24 HIV-infected patients receiving antiretroviral therapy showed that 3 injections of VAC-3S given 4 weeks apart were ...